Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
85 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Biotherapeutics Clinical Site 132
Calgary, Alberta, Canada
- Arcutis Biotherapeutics Clinical Site 207
Surrey, British Columbia, Canada
- Arcutis Biotherapeutics Clinical Site 226
Surrey, British Columbia, Canada
- Arcutis Biotherapeutics Clinical Site 232
Winnepeg, Manitoba, Canada
- Arcutis Biotherapeutics Clinical Site 234
Fredericton, New Brunswick, Canada
- Arcutis Biotherapeutics Clinical Site 205
Ajax, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 218
Barrie, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 103
London, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 133
Mississauga, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 140
Ottawa, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 109
Peterborough, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 235
Toronto, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 106
Waterloo, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 204
Windsor, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 107
Montreal, Quebec, Canada
- Arcutis Biotherapeutics Clinical Site 126
Québec, Quebec, Canada
- Arcutis Clinical Site 601
Santo Domingo, Dominican Republic
- Arcutis Biotherapeutics Clinical Site 203
Scottsdale, Arizona, United States
- Arcutis Biotherapeutics Clinical Site 239
Beverly Hills, California, United States
- Arcutis Biotherapeutics Clinical Site 127
Encinitas, California, United States
- Arcutis Biotherapeutics Clinical Site 225
Encino, California, United States
- Arcutis Biotherapeutics Clinical Site 509
Fountain Valley, California, United States
- Arcutis Biotherapeutics Clinical Site 112
Fremont, California, United States
- Arcutis Biotherapeutics Clinical Site 120
Irvine, California, United States
- Arcutis Biotherapeutics Clinical Site 508
Los Angeles, California, United States
- Arcutis Biotherapeutics Clinical Site 511
Rancho Santa Margarita, California, United States
- Arcutis Biotherapeutics Clinical Site 123
San Diego, California, United States
- Arcutis Biotherapeutics Clinical Site 220
San Diego, California, United States
- Arcutis Biotherapeutics Clinical Site 136
San Francisco, California, United States
- Arcutis Biotherapeutics Clinical Site 208
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 215
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 223
Boynton Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 237
DeLand, Florida, United States
- Arcutis Biotherapeutics Clinical Site 118
Delray Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 202
Hialeah, Florida, United States
- Arcutis Biotherapeutics Clinical Site 228
Largo, Florida, United States
- Arcutis Biotherapeutics Clinical Site 131
Miami, Florida, United States
- Arcutis Biotherapeutics Clinical Site 201
North Miami Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 137
Ocala, Florida, United States
- Arcutis Biotherapeutics Clinical Site 105
Sanford, Florida, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Feb 2020
- Primary completion
- 22 Jan 2024
- Completion
- 22 Jan 2024
- Last update posted
- 7 Jan 2025
- Registered enrollment
- 333
- Registry id
- NCT04286607
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.